The Network for Excellence in Neuroscience Clinical Trials, or NeuroNEXT, was created to conduct studies of treatments for neurological diseases through partnerships with academia, private foundations, and industry. The network is designed to expand the National Institute of Neurological Disorders and Stroke's (NINDS) capability to test promising new therapies, increase the efficiency of clinical trials before embarking on larger studies, and respond quickly as new opportunities arise to test promising treatments for people with neurological disorders. The NeuroNEXT program aims to:
- Provide a robust, standardized, and accessible infrastructure to facilitate rapid development and implementation of protocols in neurological disorders affecting adult and/or pediatric populations.
- The network includes multiple Clinical Sites, one Clinical Coordinating Center (CCC) and one Data Coordinating Center (DCC).
- Support scientifically sound, possibly biomarker-informed, Phase II clinical trials that provide data for clear go/no-go decisions.
- Energize and mobilize federal, industry, foundations and patient advocacy partners by leveraging existing relationships between NINDS and NeuroNEXT to organize high impact Phase II clinical trials for neurological disorders.
- Expand the pool of experienced clinical investigators and research staff who are prepared to be leaders of multicenter clinical research trials.
- Principal Investigator: Karen Marder, MD, MPH (Columbia)
- Principal Investigator: Claudia A. Chiriboga, MD, MPH (Columbia)
- Principal Investigator: Susan Gauthier, DO, MPH (Weill Cornell)
- Project Manager: Joyce Ann Moran, CCRC, Phone: (212) 305-8367
- CUIMC and Weill Cornell Medical College in the News
- Recent NeuroNEXT Publications
Current NeuroNEXT studies:
Join the CUMC-WCMC NeuroNEXT Network
Columbia-Weill Cornell is establishing a network of affiliate neurologists/neurosurgeons and organizations to participate in NeuroNEXT studies. As a NeuroNEXT affiliate, you will receive occasional e-mails about upcoming clinical trials and events. To be placed on our e-mail list, please contact Joyce Ann Moran at email@example.com.
How to Submit a Proposal?
Develop an idea and call one of our team members. We will be happy to guide you through the process to complete the Clinical Study Concept Synopsis. For more information, visit www.neuronext.org/researchers
The NeuroNEXT Fellowship program is an initiative to provide research experiences and career enhancement opportunities to early-stage investigators. This program is geared to develop future clinical trialists.
o The NeuroNEXT Fellowship program is an initiative to provide research experiences and career enhancement opportunities to early-stage investigators. This program is geared to develop future clinical trialists.
o The goal of this program is to prepare the individual to work towards obtaining a K award or to obtain foundation or other independent research support by the end of their NeuroNEXT fellowship.
o Awardees will be funded by NINDS for @20,000 (approximately 10% effort) of salary, inclusive of fringe.
o Prior NeuroNEXT fellows:
- 2018-2019: Nora Vanegas-Arroyave, MD
- 2019-2020: Victoria Leavitt, PhD
- 2020-2021: Rebecca Straus-Farber, MD
- 2020-2021: Imama Naqvi, MD
o 2021-2022 NeuroNEXT Fellowship Program Application Materials: Due March 31, 2021. Please send completed application packet to Joyce Ann Moran at firstname.lastname@example.org.
§ 1-page personal statement
§ A letter from the Division Chief agreeing to protected time
§ A templated synopsis of the planned research proposal, if available
- If you would like to be notified of upcoming NeuroNEXT events, please email Joyce Ann Moran at email@example.com.